Social Anxiety Disorder Market

 

Key Highlights

 

  • According to the National Institute of Mental Health (NIMH), approximately 7.1% of the US adults had social anxiety disorder in the past year. Out of the adults with social anxiety disorder in the past year, an estimated 29.9% had serious impairment. Also, data from the National Comorbidity Survey reveals that social anxiety disorder is the third most common psychiatric condition after major depression and alcohol dependence.

 

  • Social Anxiety Disorder epidemiology is segmented as 12-month Diagnosed Prevalent Cases of Social Anxiety Disorder, Gender-specific Cases of Social Anxiety Disorder, Age-specific Cases of Social Anxiety Disorder, Severity Specific Cases of Social Anxiety Disorder, and Total Treated Cases of Social Anxiety Disorder in the Social Anxiety Disorder market report.

 

Request for unlock CAGR of  Social Anxiety Disorder Market

 

DelveInsight’s “Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Social Anxiety Disorder, historical and forecasted epidemiology as well as the Social Anxiety Disorder market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

The Social Anxiety Disorder market report provides current treatment practices, emerging drugs, Social Anxiety Disorder market share of individual therapies, and current and forecasted Social Anxiety Disorder market size from 2019 to 2032, segmented by seven major markets. The report also covers current Social Anxiety Disorder treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

Geography Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan

 

Study period: 2019–2032

 

Social Anxiety Disorder Market: Understanding and Treatment Algorithm

The DelveInsight’s Social Anxiety Disorder market report gives a thorough understanding of Social Anxiety Disorder by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Social Anxiety disorder, also called Social Phobia, is the most common mental health condition which causes extreme fear in social settings, and an intense, persistent fear of being watched and judged by others. People with social anxiety disorder have trouble talking to people, meeting new people, attend social gatherings which can also affect day-to-day activities.

 

Social anxiety disorder can make a person fear from being judged or scrutinized by others. Patients may understand that their fears are irrational or unreasonable, but feel powerless to overcome them. Social anxiety is different from shyness which is usually short-term and doesn’t disrupt one’s life. Social anxiety is persistent and debilitating. It can affect one’s ability to work, attend school, and develop close relationships with people outside of their family. Symptoms of Social Anxiety disorder may include physical symptoms which can be blushing, nausea, excessive sweating, trembling or shaking, difficulty in speaking, dizziness or lightheadedness, and rapid heart rate.

 

It can also include several psychological symptoms which are worrying intensely about social situations, worrying for days or weeks before an event, avoiding social situations or trying to blend into the background, worrying about embarrassing themselves in a social situation, worrying that other people will notice them stressed or nervous, and needing alcohol to face a social situation.

 

Social Anxiety Disorder Diagnosis

A health professional can provide a diagnosis and individualized treatment plan for social anxiety disorder. Both cognitive-behavioral therapy (CBT) and medication are scientifically proven effective treatments. A healthcare provider such as a clinician, psychologist, psychiatrist, or therapist can diagnose a person with social anxiety disorder based on the criteria for social anxiety disorder listed in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) published by the American Psychiatric Association. A person typically has to have had symptoms of social anxiety disorder for at least six months to be diagnosed.

 

Social Anxiety Disorder Treatment

Generally, it requires about 12 to 16 therapy sessions. The goal is to build confidence, learn skills that help manage the situations that scare the most, and then get out into the world. The doctor may suggest antidepressants to treat social anxiety disorder. Anti-anxiety medications are typically used for shorter periods. Blood pressure medication such as beta-blockers can be used for symptoms of social anxiety disorder as well. For instance, they may prescribe drugs known as SSRIs (selective serotonin reuptake inhibitors), such as Fluoxetine, Paroxetine, Sertraline, etc., SNRIs (serotonin-norepinephrine reuptake inhibitors), such as Venlafaxine or duloxetine, Benzodiazepines such as Lorazepam or alprazolam, and Beta-blockers such as Propranolol or metoprolol.

 

Social Anxiety Disorder Epidemiology

The Social Anxiety Disorder epidemiology section provides insights into the historical and current Social Anxiety Disorder patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Social Anxiety Disorder report also provides the diagnosed patient pool, their trends, and assumptions undertaken.

 

Key findings

 

  • According to the National Institute of Mental Health (NIMH), approximately 7.1% of the US adults had social anxiety disorder in the past year. Out of the adults with social anxiety disorder in the past year, an estimated 29.9% had serious impairment. Also, data from the National Comorbidity Survey reveals that social anxiety disorder is the third most common psychiatric condition after major depression and alcohol dependence.

 

  • The Social Anxiety Disorder epidemiology covered in the report provides historical as well as forecasted Social Anxiety Disorder epidemiology [segmented as 12-month Diagnosed Prevalent Cases of Social Anxiety Disorder, Gender-specific Cases of Social Anxiety Disorder, Age-specific Cases of Social Anxiety Disorder, Severity Specific Cases of Social Anxiety Disorder, and Total Treated Cases of Social Anxiety Disorder in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

 

Country-wise Social Anxiety Disorder Epidemiology

The epidemiology segment also provides the Social Anxiety Disorder epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Learn more about the evolving epidemiology trends and key developments: Social Anxiety Disorder Epidemiology Forecast
 

Social Anxiety Disorder Drug Chapters

The drug chapter segment of the Social Anxiety Disorder report encloses a detailed analysis of Social Anxiety Disorder marketed drugs and late-stage (Phase III and Phase II) Social Anxiety Disorder pipeline drugs. It also helps understand the Social Anxiety Disorder clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Emerging Social Anxiety Disorder Drugs

The report details the emerging Social Anxiety Disorder therapies under the late and mid-stage of development for Social Anxiety Disorder treatment.

 

Social Anxiety Disorder Market Outlook

The Social Anxiety Disorder market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Social Anxiety Disorder market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

 

This segment gives a thorough detail of the Social Anxiety Disorder market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Social Anxiety Disorder market in 7MM is expected to witness a major change in the study period 2019–2032.

 

Key findings

This section includes a glimpse of the Social Anxiety Disorder market in 7MM.

 

The United States: Social Anxiety Disorder Market Outlook

  • This section provides the total Social Anxiety Disorder market size and market size by therapies in the United States.

 

EU4 and the UK Countries: Social Anxiety Disorder Market Outlook

  • The total Social Anxiety Disorder market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan: Social Anxiety Disorder Market Outlook

  • The total Social Anxiety Disorder market size and market size by therapies in Japan are also mentioned.

 

Social Anxiety Disorder Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Social Anxiety Disorder market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Social Anxiety Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. 

 

This will help in understanding the Social Anxiety Disorder drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

 

Social Anxiety Disorder Pipeline Development Activities

The report provides insights into different therapeutic candidates in the Phase II, and Phase III stages. It also analyses Social Anxiety Disorder’s key players involved in developing targeted therapeutics.

 

Social Anxiety Disorder Clinical Trial Development Activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information on Social Anxiety Disorder emerging therapies.

 

Social Anxiety Disorder Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Social Anxiety Disorder domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Social Anxiety Disorder market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

 

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Social Anxiety Disorder market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Scope of the Social Anxiety Disorder Market Report

  • Descriptive overview of Social Anxiety Disorder, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
  • Comprehensive insight into the Social Anxiety Disorder epidemiology and forecasts in the 7MM
  • An all-inclusive account of both the current and emerging therapies for Social Anxiety Disorder, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
  • Exhaustive analysis of the Social Anxiety Disorder market; historical and forecasted covering drug outreach in the 7MM
  • Detailed Patient Based Market Forecasting determines the trends shaping and driving the global Social Anxiety Disorder market

 

Social Anxiety Disorder Market Report Highlights

  • In the coming years, the Social Anxiety Disorder market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Social Anxiety Disorder R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition  
  • Major players are involved in developing Social Anxiety Disorder therapies. The launch of emerging therapies will significantly impact the Social Anxiety Disorder market
  • A better understanding of Social Anxiety Disorder pathogenesis will also contribute to the development of novel therapeutics for Social Anxiety Disorder
  • Our in-depth analysis of the Social Anxiety Disorder pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Social Anxiety Disorder Report Insights

  • Patient Based Market Forecasting
  • Therapeutic approaches
  • Social Anxiety Disorder pipeline analysis
  • Social Anxiety Disorder market size and trends
  • Social Anxiety Disorder market opportunities
  • Impact of upcoming therapies

 

Social Anxiety Disorder Report Key Strengths

  • 11 years forecast
  • 7MM Coverage
  • Social Anxiety Disorder epidemiology segmentation
  • Key cross competition
  • KOL views
  • Social Anxiety Disorder drugs uptake

 

Social Anxiety Disorder Report Assessment

  • Current treatment practices
  • Unmet needs
  • Social Anxiety Disorder pipeline product profiles
  • Social Anxiety Disorder market attractiveness

 

Key Questions

  • Social Anxiety Disorder market insights:
  • What would be the Social Anxiety Disorder market growth till 2032, and what will be the resultant market size in 2032?
  •  What was the Social Anxiety Disorder drug class share (in percentage) distribution in 2019, and how would it look in 2032?
  • What would be the Social Anxiety Disorder total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
  • What are the key findings of the market across 7MM, and which country will have the largest Social Anxiety Disorder market size during the forecast period (2019–2032)?
  • How would the unmet needs affect the Social Anxiety Disorder market dynamics and subsequent analysis of the associated trends?

 

Social Anxiety Disorder Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of Social Anxiety Disorder?
  • What is the historical and forecasted Social Anxiety Disorder patient pool in 7MM, and where can one observe the highest patient population and growth opportunities?
  • What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
  • ent Treatment Scenario, Marketed Drugs, and Emerging Therapies
  • What are the current treatment guidelines and treatment options, in addition to approved therapies for Social Anxiety Disorder in the US, Europe, and Japan?
  • What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Social Anxiety Disorder therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Social Anxiety Disorder and its status, along with the challenges faced?

 

Reasons to Buy

  • The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Social Anxiety Disorder market
  • Organize sales and marketing efforts by identifying the best opportunities for Social Anxiety Disorder in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan
  • Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors

Frequently Asked Questions

What is the Social Anxiety Disorder?
Social Anxiety disorder (SAD), also called Social Phobia, is the most common mental health condition which causes extreme fear in social settings, and an intense, persistent fear of being watched and judged by others. Social Anxiety disorder symptoms may include physical symptoms which can be blushing, nausea, excessive sweating, trembling or shaking, difficulty in speaking, dizziness or lightheadedness, and rapid heart rate.
Who are the leading companies in the Social Anxiety Disorder Market Landscape?
The leading companies that are working in the Vistagen Therapeutics, Bionomics, and several others
What are the Key strengths of Social Anxiety Disorder Market Report?
Key strengths of Social Anxiety Disorder Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers and Market Barriers.
Which country is expected to account for the most significant prevalent cases for Social Anxiety Disorder in the 7MM?
The US is expected to account for the highest Social Anxiety Disorder prevalent cases.

1. Key Insights

2. Executive Summary of Social Anxiety Disorder (SAD)

3. Competitive Intelligence Analysis for Social Anxiety Disorder (SAD)

4. Social Anxiety Disorder (SAD): Market Overview at a Glance

4.1. Social Anxiety Disorder (SAD) Total Market Share (%) Distribution in 2019

4.2. Social Anxiety Disorder (SAD) Total Market Share (%) Distribution in 2032

5. Social Anxiety Disorder (SAD): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Social Anxiety Disorder (SAD) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Social Anxiety Disorder (SAD) Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.4.1. Social Anxiety Disorder (SAD) Epidemiology Scenario in the United States (2019-2032)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Social Anxiety Disorder (SAD) Epidemiology Scenario in Germany (2019-2032)

7.5.2. France Epidemiology

7.5.2.1. Social Anxiety Disorder (SAD) Epidemiology Scenario in France (2019-2032)

7.5.3. Italy Epidemiology

7.5.3.1. Social Anxiety Disorder (SAD) Epidemiology Scenario in Italy (2019-2032)

7.5.4. Spain Epidemiology

7.5.4.1. Social Anxiety Disorder (SAD) Epidemiology Scenario in Spain (2019-2032)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Social Anxiety Disorder (SAD) Epidemiology Scenario in the United Kingdom (2019-2032)

7.5.6. Japan Epidemiology

7.5.6.1. Social Anxiety Disorder (SAD) Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Social Anxiety Disorder (SAD) Treatment and Management

8.2. Social Anxiety Disorder (SAD) Treatment Algorithm

9. Social Anxiety Disorder (SAD) Unmet Needs

10. Key Endpoints of Social Anxiety Disorder (SAD) Treatment

11. Social Anxiety Disorder (SAD) Marketed Products

11.1. List of Social Anxiety Disorder (SAD) Marketed Drugs in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Social Anxiety Disorder (SAD) Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Social Anxiety Disorder (SAD): Seven Major Market Analysis

13.1. Key Findings

13.2. Social Anxiety Disorder (SAD) Market Size in 7MM

13.3. Social Anxiety Disorder (SAD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Social Anxiety Disorder (SAD) Total Market Size in the United States

15.1.2. Social Anxiety Disorder (SAD) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Social Anxiety Disorder (SAD) Total Market Size in Germany

15.3.2. Social Anxiety Disorder (SAD) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Social Anxiety Disorder (SAD) Total Market Size in France

15.4.2. Social Anxiety Disorder (SAD) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Social Anxiety Disorder (SAD) Total Market Size in Italy

15.5.2. Social Anxiety Disorder (SAD) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Social Anxiety Disorder (SAD) Total Market Size in Spain

15.6.2. Social Anxiety Disorder (SAD) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Social Anxiety Disorder (SAD) Total Market Size in the United Kingdom

15.7.2. Social Anxiety Disorder (SAD) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Social Anxiety Disorder (SAD) Total Market Size in Japan

15.8.3. Social Anxiety Disorder (SAD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Social Anxiety Disorder (SAD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary.

List of Table

Table 1: 7MM Social Anxiety Disorder (SAD) Epidemiology (2019-2032)

Table 2: 7MM Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases (2019-2032)

Table 3: Social Anxiety Disorder (SAD) Epidemiology in the United States (2019-2032)

Table 4: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Social Anxiety Disorder (SAD) Epidemiology in Germany (2019-2032)

Table 6: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Social Anxiety Disorder (SAD) Epidemiology in France (2019-2032)

Table 8: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Social Anxiety Disorder (SAD) Epidemiology in Italy (2019-2032)

Table 10: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Social Anxiety Disorder (SAD) Epidemiology in Spain (2019-2032)

Table 12: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Social Anxiety Disorder (SAD) Epidemiology in the UK (2019-2032)

Table 14: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in the UK (2019-2032)

Table 15: Social Anxiety Disorder (SAD) Epidemiology in Japan (2019-2032)

Table 16: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in Japan (2019-2032)

Table 17: Drug Name, Clinical Trials by Recruitment status

Table 18: Drug Name, Clinical Trials by Zone

Table 19: Total Seven Major Market Size in USD, Million (2019-2032)

Table 20: Region-wise Market Size in USD, Million (2019-2032)

Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Table 22: United States Market Size in USD, Million (2019-2032)

Table 23: United States Market Size by Therapy in USD, Million (2019-2032)

Table 24: Germany Market Size in USD, Million (2019-2032)

Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Table 26: France Market Size in USD, Million (2019-2032)

Table 27: France Market Size by Therapy in USD, Million (2019-2032)

Table 28: Italy Market Size in USD, Million (2019-2032)

Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Table 30: Spain Market Size in USD, Million (2019-2032)

Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Table 32: United Kingdom Market Size in USD, Million (2019-2032)

Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Table 34: Japan Market Size in USD, Million (2019-2032)

Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of tables is not exhaustive; the final content may vary

List of Figures

Figure 1: 7MM Social Anxiety Disorder (SAD) Epidemiology (2019-2032)

Figure 2: 7MM Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases (2019-2032)

Figure 3: Social Anxiety Disorder (SAD) Epidemiology in the United States (2019-2032)

Figure 4: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5: Social Anxiety Disorder (SAD) Epidemiology in Germany (2019-2032)

Figure 6: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7: Social Anxiety Disorder (SAD) Epidemiology in France (2019-2032)

Figure 8: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in France (2019-2032)

Figure 9: Social Anxiety Disorder (SAD) Epidemiology in Italy (2019-2032)

Figure 10: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11: Social Anxiety Disorder (SAD) Epidemiology in Spain (2019-2032)

Figure 12: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13: Social Anxiety Disorder (SAD) Epidemiology in the UK (2019-2032)

Figure 14: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in the UK (2019-2032)

Figure 15: Social Anxiety Disorder (SAD) Epidemiology in Japan (2019-2032)

Figure 16: Social Anxiety Disorder (SAD) Diagnosed and Treatable Cases in Japan (2019-2032)

Figure 17: Drug Name, Clinical Trials by Recruitment status

Figure 18: Drug Name, Clinical Trials by Zone

Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)

Figure 20: Region-wise Market Size in USD, Million (2019-2032)

Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Figure 22: United States Market Size in USD, Million (2019-2032)

Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)

Figure 24: Germany Market Size in USD, Million (2019-2032)

Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Figure 26: France Market Size in USD, Million (2019-2032)

Figure 27: France Market Size by Therapy in USD, Million (2019-2032)

Figure 28: Italy Market Size in USD, Million (2019-2032)

Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Figure 30: Spain Market Size in USD, Million (2019-2032)

Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Figure 32: United Kingdom Market Size in USD, Million (2019-2032)

Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Figure 34: Japan Market Size in USD, Million (2019-2032)

Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of figures is not exhaustive; the final content may vary

Forward to Friend

Need A Quote